Clinical trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS
NCT06062810 is registered in ClinicalTrials.gov with Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- June 21, 2025
- Completion date
- December 28, 2026
- Enrollment
- 600 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer